🇺🇸 FDA
Pipeline program

CT-0525

Study 102

Phase 1 small_molecule active

Quick answer

CT-0525 for HER2-positive is a Phase 1 program (small_molecule) at Carisma Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Carisma Therapeutics
Indication
HER2-positive
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials